Examining risk mitigation best practices and exploring emerging challenges/opportunities for an expanding cell and gene therapy sector

• What lessons has the cell and gene therapy field learned about the raw and starting materials supply chain from the COVID-19 pandemic?
• What is the latest progress in ensuring a sufficient supply of starting materials for specific, rapidly expanding cell and gene therapy technology areas?
  • Eg. how are donor management strategies and cell conversion methods evolving to enable the allogeneic cell therapy field?
• Driving improvements in the consistency, reproducibility and traceability of reagents and other critical raw/ancillary materials for cell and gene therapy manufacture
• How to predict, measure and manage the impact downstream of variability in cell therapy starting materials?
• Key considerations and preparations for effectively managing materials supply risk and meeting regulatory requirements in the post-market approval setting.